← Back to Search

Surgical Patients with benign pathology for Pancreatic Cancer

N/A

Waitlist Available

Led By Andrew Judge, PhD

Research Sponsored by University of Florida

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Pancreatic Cancer Patients who are potentially surgically resectable.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately 2 years

Awards & highlights

Study Summary

This trial will study the relationship between muscle wasting and outcomes in pancreatic cancer patients in order to improve quality of life and increase overall survival.

Eligible Conditions

Pancreatic Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

You have pancreatic cancer that can be removed through surgery.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Identify gene networks within the skeletal muscle between the groups

Myofiber atrophy in muscle tissue samples between the groups

Ultrastructural abnormalities in muscle tissue samples between the groups

Secondary outcome measures

Blood Chemistry composite

History of weight lost

Lymphatic Metastasis

+4 more

Trial Design

2Treatment groups

Active Control

Group I: Surgical Patients with benign pathologyActive Control1 Intervention

During surgical resection for patients with benign right upper quadrant pathology, a muscle tissue biopsy sample will be performed.

Group II: Pancreatic Cancer PatientsActive Control1 Intervention

During the surgical resection for the pancreatic cancer a muscle tissue biopsy sample will be performed.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor

1,339 Previous Clinical Trials

717,355 Total Patients Enrolled

The V Foundation for Cancer ResearchOTHER

18 Previous Clinical Trials

1,268 Total Patients Enrolled

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NIH

483 Previous Clinical Trials

1,086,939 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the age criterion for this clinical trial extend beyond 35 years of age?

"The lower age limit for admission into this medical trial is 18 and the upper boundary is 80, as specified in its inclusion criteria."

Answered by AI

How many participants are being included in this clinical experiment?

"Yes, the data from clinicaltrials.gov shows that this trial is actively enrolling participants. It was first launched on March 1st 2016 and was recently revised on February 4th 2021. The study requires 200 individuals to be recruited across a single medical centre."

Answered by AI

Is it still possible to join this experimental research project?

"As per clinicaltrials.gov, this research project is in the midst of recruiting subjects. Initially advertised on March 1st 2016 and last modified February 4th 2021, it seeks to expand its sample size."

Answered by AI

Am I qualified to join the research project?

"Aspiring participants must have wasting syndrome and be between 18 to 80 years of age in order to qualify for this medical trial. Approximately 200 patients are required for the study's completion."

Answered by AI

What are the desired outcomes of this experiment?

"This investigation, which is to be assessed over a 24-hour period, aims to compare the level of myofiber atrophy in muscle tissue samples between two groups. Secondary objectives include measuring tumor grade at pathologic assessment and during routine examination, tracking survival data through regular checkups, as well as evaluating nutritional status with clinical evaluation at treatment follow-up."

Answered by AI

Recent research and studies

Clinical NutritionJournal

Cachexia: A New Definition

Evans, William J., John E. Morley, Josep Argilés, Connie Bales, Vickie Baracos, Denis Guttridge, Aminah Jatoi, et al.. 2008. “Cachexia: A New Definition”. Clinical Nutrition. Elsevier BV. doi:10.1016/j.clnu.2008.06.013.

Physiological ReviewsJournal

Mechanisms of Cancer Cachexia

Tisdale, Michael J.. 2009. “Mechanisms of Cancer Cachexia”. Physiological Reviews. American Physiological Society. doi:10.1152/physrev.00016.2008.

clinicaltrials.govStudy

The Role of Muscle Cachexia in Pancreatic Cancer

2016. "The Role of Muscle Cachexia in Pancreatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02515513.